BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jun 06, 2011
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 6/3 close
AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) Baird Christopher Raymond Upgrade Market outperform (from neutral) 7% $17.92
Raymond also raised his target to $22 from $19, saying he thinks AMAG shares have "bottomed" and expects the stock to rebound. Raymond said recent script data and surveys of nephrologists indicate that Feraheme ferumoxytol "may be turning a corner commercially." He expects FY11 Feraheme revenue to come in at $58M vs. $55M analyst consensus. The IV iron replacement therapeutic is approved to treat iron...

Read the full 605 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >